Antifungal Echinocandin
DOI:
https://doi.org/10.55175/cdk.v46i2.512Keywords:
Antifungal, echinocandin, caspofungin, micafungin, anidulafungin, kandidiasisAbstract
Infeksi fungal invasif (IFI) masih menjadi penyebab utama morbiditas dan mortalitas pasien immunocompromised. Pilihan antifungal yang tersedia untuk IFI terbatas pada polyene, triazole, dan echinocandin. Echinocandin, yang terdiri dari caspofungin, micafungin, dan anidulafungin, merupakan golongan antifungal terbaru yang saat ini banyak digunakan untuk pengobatan IFI. Echinocandin memiliki beberapa keunggulan seperti aktivitas fungisidal yang poten terhadap sebagian besar spesies Candida, rendahnya resistensi, profil keamanan yang lebih baik serta interaksi dengan obat lain yang lebih sedikit.
Invasive fungal infection (IFI) is still a major cause of morbidity and mortality in immunocompromised patients. The antifungal choices available for IFI are limited to polyene, triazole, and echinocandin. Echinocandin, which consists of caspofungin, micafungin, and anidulafungin, is the newest class of antifungal which is currently widely used for the treatment of IFI. Echinocandin has several advantages such as potent fungicidal activity against most Candida species, low resistance, better safety profile and fewer drug interaction.
Downloads
References
Chang YL, Yu SJ, Heitman J, Wellington M, Chen YL. New facets of antifungal therapy. Virulence. 2017;8(2):222-236. doi: 10.1080/21505594.2016.1257457. Epub 2016 Nov 7.
Denning DW, Bromley MJ. Infectious Disease. How to bolster the antifungal pipeline. Science 2015; 347:1414-6; PMID:25814567
Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C,Ezzati M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2163-96; PMID:23245607;http://dx.doi.org/10.1016/S0140-6736(12)61729-2
Yapar N. Epidemiology and risk factors for invasive candidiasis. Ther Clin Risk Manag. 2014; 10: 95–105.
Perfect JR, Hachem R, Wingard JR. Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients. Clin Infect Dis 2014; 59 Suppl 5:S352-5; PMID:25352630; http://dx.doi.org/10.1093/cid/ciu639
Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA et al. Coccidioidomycosis.Clin Infect Dis 2005; 41:1217-23; PMID:16206093; http://dx.doi.org/10.1086/496991
Chapman SW, Dismukes WE, Proia LA, Bradsher RW, Pappas PG, Threlkeld MG et al. Clinical practice guidelines for the management of blastomycosis:2008 update by the Infectious Diseases Society of America.Clin Infect Dis 2008; 46:1801-12; PMID:18462107;http://dx.doi.org/10.1086/588300
Wheat LJ, Freifeld AG, Kleiman MB, Baddley JW, McKinsey DS, Loyd JE et al. Clinical practice guidelines for the management of patients with histoplasmosis:2007 update by the Infectious Diseases Society of America. Clin Infect Dis 2007; 45:807-25;PMID:17806045; http://dx.doi.org/10.1086/521259
Roemer T, Krysan DJ. Antifungal drug development: challenges, unmet clinical needs, and new approaches. Cold Spring Harb Perspect Med 2014; 4:a019703;http://dx.doi.org/10.1101/cshperspect.a019703
Paramythiotou E, Frantzeskaki F, Flevari A, Armaganidis A, Dimopoulos G. Invasive fungal infections in the ICU: how to approach, how to treat. Molecules. 2014;19(1):1085-119. doi: 10.3390/molecules19011085.
Vincent JL, Rello J, Marshall J, Silva E, Anzueto A, Martin CD et al. International study of the prevalence and outcomes of infection in intensive care units. JAMA 2009; 21: 2323-9.
Pappas PG, Silveira FP. Candida in solid organ transplant recipients. Am J Transplant. 2009;9 Suppl 4:S173-9. doi: 10.1111/j.1600-6143.2009.02909.x.
Kalista KF, Chen LK, Wahyuningsih R, Rumende CM. Karakteristik Klinis dan Prevalensi Pasien Kandidiasis Invasif di Rumah Sakit Cipto Mangunkusumo. J Penyakit Dalam Indon. 2017;4(2):56-61. doi: http://dx.doi.org/10.7454/jpdi.v4i2.104.
Hajjeh RA, Sofair AN, Harrison LH, Lyon GM, Arthington-Skaggs BA, Mirza SA et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 2004;42:1519-27.
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ, et al. Epidemiology and outcomes ofcandidemia in 2019 patients: Data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 2009; 48: 1695–1703.
Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: A 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. J. Clin. Microbiol. 2005; 43: 5848-59.
Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the various non–albicans Candida spp among candidemia isolates from inpatients in various parts of the world: A systematic review. Int. J. Infect. Dis. 2010;14: e954–96
Shorr AF, Lazarus DR, Sherner, JH, Jackson WL, Morrel M, Fraser VJ et al.Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit. Care Med. 2007; 35: 1077-83.
Kofla G, Ruhnke M. Pharmacology and metabolism of anidulafungin, caspofungin and micafungin in the treatment of invasive candidosis: review of the literature. Eur J Med Res 2011; 16:159-66; PMID:21486730; http://dx.doi.org/10.1186/2047-783X-16-4-159
Stover KR, Farley JM, Kyle PB, Cleary JD. Cardiac toxicity of some echinocandin antifungals. Expert Opin Drug Saf 2014; 13:5-14; PMID:24047086 ; http://dx.doi.org/ 10.1517/14740338.2013.829036
Moriyama B, Gordon LA, McCarthy M, Henning SA, Walsh TJ, Penzak SR. Emerging drugs and vaccines for candidemia. Mycoses 2014; 57:718-33; PMID:25294098; http://dx.doi.org/10.1111/myc.12265
Walker SS, Xu Y, Triantafyllou I, Waldman MF, Mendrick C, Brown N, et al. Discovery of a novel class of orally active antifungal beta-1,3-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2011; 55:5099-106; PMID:21844320; http://dx.doi.org/10.1128/AAC.00432-11
Fink M, Zerlauth U, Kaulfersch C, Rab A, Alberer D, Preiss P et al. A severe case of haemodynamic instability during anidulafungin administration. J Clin Pharm Ther 2013; 38:241-2; PMID:23550735 ; http://dx.doi.org/10.1111/jcpt.12046
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of america. Clin Infect Dis 2015; 62:e1-50; PMID:26679628
Nett JE, Andes DR. Antifungal agents: spectrum of activity, pharmacology, and clinical indications. Infect Dis Clin North Am 2016; 30:51-83; PMID:26739608; http://dx.doi.org/10.1016/j.idc.2015.10.012
Arendrup MC, Cuenca-Estrella M, Lass-Fl€orl C, Hope WW. Breakpoints for antifungal agents: An update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp. Drug Resist Updat 2013; 16:81-95; PMID:24618110 ; http:// dx.doi.org/10.1016/j.drup.2014.01.001
Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51:513-21; PMID:12615851 ; http://dx. doi.org/10.1093/jac/dkg117
Chamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical Effect of Echinocandins across Candida Species In Vitro: Evidence for Echinocandin-Specific and Candida Species-Related Differences. Antimicrob Agents Chemother. 2007; 51(6): 2257-59.
Fleischhacker M, Radecke C, Schulz B, Ruhnke M. Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis. Eur J Clin Microbiol Infect Dis. 2008;27(2):127-31. Epub 2007 Dec 4.
Bal AM. The echinocandins: three useful choices or three too many?.Int J Antimicrob Agents. 2010;35(1):13-8. doi: 10.1016/j.ijantimicag.2009.09.011. Epub 2009 Nov 25.
Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 2002;49:973–80.
Mukherjee PK, Chandra J. Candida biofilm resistance. Drug Resist Update 2004;7:301–9.
Sanglard D, Ischer F, Monod M, Bille J. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: characterization of CDR2, a new multidrug ABC transporter gene. Microbiology 1997;43:405–16.
Choi HW, Shin JH, Jung SI, Park KH, Cho D, Kee SJ, et al. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals. Antimicrob Agents Chemother 2007;51:1520–3.
Cateau E, Rodier MH, Imbert C. In vitro efficacies of caspofungin or micafungin catheter lock solutions on Candida albicans biofilm growth. J Antimicrob Chemother 2008;62:153–5.
Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J Antimicrob Chemother 2009;64:567–70.
Jacobson MJ, Piper KE, Nguyen G, Steckelberg JM, Patel R. In vitro activity of anidulafungin against Candida albicans biofilms. Antimicrob Agents Chemother 2008;52:2242–3
Perlin DS. Mechanisms of echinocandin antifungal drug resistance. Ann N Y Acad Sci 2015; 1354:1-11; PMID:26190298; http://dx.doi.org/10.1111/nyas.12831
Johnson ME, Katiyar SK, Edlind TD. New Fks hot spot for acquired echinocandin resistance in Saccharomyces cerevisiae and its contribution to intrinsic resistance of Scedosporium species. Antimicrob Agents Chemother 2011; 55:3774-81; PMID:21576441 ; http://dx.doi.org/ 10.1128/AAC.01811-10
Peman J, Canton E, Espinel-Ingroff A. Antifungal drug resistance mechanisms. Expert Rev Anti Infect Ther 2009; 7:453-60; http://dx.doi.org/10.1586/eri.09.18
Yeoh SF, Lee TJ, Chew KL, Lin S, Yeo D, Setia. S. Echinocandins for management of invasive candidiasis in patients with liver disease and liver transplantation. Infect Drug Resist. 2018; 11: 805–19.
Muilwijk EW, Lempers VJC, Burger DM, Warris A, Pickkers P, Aarnoutse RE et al. Impact of special patient populations on the pharmacokinetics of echinocandins. Expert Rev Anti Infect Ther 2015; 13:799-815; PMID:25947367; http://dx.doi.org/10.1586/ 14787210.2015.1028366
Saner F, Gensicke J, Rath P, Fruhauf N, Gu Y, Paul A et al. Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 2006; 34:328-32; PMID:17180587; http://dx.doi.org/10.1007/s15010-006-5657-8
Undre NA, Stevenson P, Wilbraham D. Pharmacokinetic profile of micafungin when co-administered with amphotericin B in healthy male subjects. Int J Clin Pharmacol Ther 2014; 52:237-44; http://dx.doi.org/10.5414/CP202015
Caspofungin. Medscape [Internet] 2018 [Cited 2018 October 24]. Available from: https://reference.medscape.com/drug/cancidas-caspofungin-342584.
Micafungin. Medscape [Internet] 2018 [Cited 2018 October 24]. Available from: https://reference.medscape.com/drug/mycamine-micafungin-342585.
Anidulafungin. Medscape [Internet] 2018 [Cited 2018 October 24]. Available from: https://reference.medscape.com/drug/ecalta-eraxis-anidulafungin-342599
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 https://creativecommons.org/licenses/by-nc/4.0/
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
